Key result
Novel molecular biomarkers showed potential for predicting cancer therapy-induced cardiotoxicity, with AUCs >0.73, ORs 0.26-7.17, and HRs 1.28-1.80, though clinical use is not yet recommended.
Why the study?
Cancer treatments are associated with cardiotoxic events that predispose to cardiac pathology and compromise survival, necessitating the identification of new molecular biomarkers to detect cardiotoxicity.
Do novel molecular biomarkers predict cancer therapy-induced cardiotoxicity in adult patients?
Do novel molecular biomarkers predict cancer therapy-induced cardiotoxicity in adult patients?
Answers are grounded in this paper and cite their sources.
While several novel molecular biomarkers show promise for predicting cancer therapy-induced cardiotoxicity, current evidence is insufficient to recommend their routine clinical use.
AIM: Cancer treatments are associated with cardiotoxic events that predispose to cardiac pathology and compromise the survival of patients, making necessary the identification of new molecular biomarkers to detect cardiotoxicity. This scoping review aims to identify the available evidence on novel molecular biomarkers associated with cardiotoxicity in the adult population undergoing cancer therapy. METHODS AND RESULTS: The databases Medline, Web of Science, Scopus, and Embase were screened for the identification of published studies until 23 August 2020, searching for novel molecular biomarkers reported in cancer therapy-related cardiac dysfunction in adult patients. A total of 42 studies that met the eligibility criteria were included. Fourteen studies reported 44 new protein biomarkers, 18 studies reported 57 new single nucleotide polymorphism biomarkers, and 11 studies reported 171 new gene expression profiles associated with cardiotoxicity. Data were extracted for 272 novel molecular biomarkers reported and evaluated in 7084 cancer patients, of which only 13 were identified in more than one study (MPO, sST2, GDF-15, TGF-B1, rs1056892, rs1883112, rs4673, rs13058338, rs1695, miR-1, miR-25-3p, miR-34a-5p, and miR-423-5p), showing values for area under the curve > 0.73 (range 0.74-0.85), odds ratio 0.26-7.17, and hazard ratio 1.28-1.80. CONCLUSIONS: Multiple studies presented a significant number of novel molecular biomarkers as promising predictors for risk assessment of cardiac dysfunction related to cancer therapy, but the characteristics of the studies carried out and the determinations applied do not allow suggesting the clinical use of these molecular biomarkers in the assessment of cancer therapy-induced cardiotoxicity.
No takes yet. Share an insight, caveat, or question.
Cartas‐Espinel et al. (2022) conducted a review in Cancer therapy-induced cardiotoxicity (n=7,084). Novel molecular biomarkers was evaluated on Cancer therapy-related cardiac dysfunction. Novel molecular biomarkers showed potential for predicting cancer therapy-induced cardiotoxicity, with AUCs >0.73, ORs 0.26-7.17, and HRs 1.28-1.80, though clinical use is not yet recommended.
Synapse has enriched 10 related papers. Consider them for comparative context: